The investigator is the party who reports to the FDA, through the sponsor, using Form 3454 or Form 3455. The sponsor then certifies the investigator's disclosures to the FDA in the marketing application. The investigator does not file these forms directly with the FDA; the sponsor transmits them as part of the submission.
This distinction trips up clinical research coordinators, site directors, and even some seasoned principal investigators. The phrase "directly to the FDA" suggests a filing relationship that does not exist for the investigator. Understanding who touches which document, in what order, and under what regulation matters for audit readiness and for the integrity of the marketing application itself. This explainer walks through the mechanism, the numbers behind enforcement, the edge cases that break the simple story, and the practical steps that keep a site compliant.
The disclosure chain: who reports what to whom
The statutory foundation is Section 708 of the FD&C Act, which Congress added in 1992 and amended in 2007 to raise the disclosure threshold from USD 10,000 to USD 25,000. The regulation implementing it lives at 21 CFR Part 54. That regulation defines "clinical investigator" and lays out the financial interests that must be disclosed to the sponsor, and it requires the sponsor to submit a certification or disclosure statement to the FDA.
The mechanics run in three links. First, the investigator discloses financial interests to the sponsor. Second, the sponsor collects those disclosures and, when it submits the marketing application, certifies either that no disclosable interests exist (Form 3454) or that interests were disclosed and how they were managed (Form 3455). Third, the FDA receives that certification or statement as part of the application.
The investigator's obligation therefore terminates at the sponsor. The sponsor is the reporting party to the FDA. An investigator who sends a Form 3454 to an FDA office has misfiled it; the form belongs in the sponsor's regulatory file and, ultimately, in the application's financial disclosure section.
Why the FDA reviews these disclosures at all
Financial interests are not prohibited. A conflict of interest is a condition, not a crime. The regulatory logic is that the FDA needs to see the financial relationship so it can evaluate whether the interest could have biased the design, conduct, or reporting of the study. The FDA's reviewers weigh disclosed interests when they assess the adequacy of the data.
The mechanism works because the sponsor sits between the money and the agency. The sponsor holds the contract, pays the investigator, and assembles the application. Requiring the sponsor to certify forces it to collect and vet the investigator's disclosures before submission. If the sponsor certifies "no interests" while its own payment records show otherwise, that is a sponsor-level integrity problem.
The 2007 amendment raised the threshold to USD 25,000 for payments to the investigator, but kept other triggers: equity interests in the sponsor, proprietary interests in the tested product, and any arrangement where the outcome could affect the investigator's compensation. The regulation also covers payments to the investigator's spouse and dependent children, which is why site disclosure forms ask about family holdings.
Quantified context: thresholds, timelines, and enforcement scale
The THRESHOLD number is USD 25,000 in aggregate payments during the study and for one year after its completion. Below that amount, payments alone do not trigger disclosure, though equity and proprietary interests do regardless of value.
The TIME course runs from study start through one year after the last study visit. Investigators must update disclosures as circumstances change, not just at signature.
The coverage figures matter for site planning. Part 54 applies to covered clinical studies, meaning studies submitted in support of an application or used to support labeling. It does not reach every trial a site runs. A Phase I study that never enters a marketing application falls outside Part 54's disclosure submission requirement, though the site may still have contractual reporting duties to the sponsor.
Enforcement scale is real but uneven. The FDA's Bioresearch Monitoring program inspects clinical investigators and sponsors, and financial disclosure deficiencies appear in inspection classification records. The agency has issued guidance on financial disclosure since the 1990s and updated the public-facing materials after the 2007 statutory change. Sponsors, not investigators, bear the submission obligation, so FDA citations for missing 3454 or 3455 forms typically land on the sponsor side of the inspection.
One counterintuitive detail: a disclosed interest does not automatically taint the data. The FDA may accept data from a study with a significant financial interest if the disclosure is complete and the agency judges the interest manageable. The failure mode that destroys credibility is the undisclosed interest, not the disclosed one. A site that over-discloses loses nothing.
Edge cases that break the simple answer
The clean rule — investigator discloses to sponsor, sponsor certifies to FDA — bends in several scenarios.
Sub-investigators and study staff. The regulation's definition of clinical investigator covers the individuals who actually conduct the study and are directly involved in the treatment or evaluation of subjects. A site's sub-investigators, and sometimes key coordinators with financial ties, may need to disclose through the site's principal investigator to the sponsor. The sponsor consolidates these into its certification. The party reporting to the FDA remains the sponsor.
Foreign studies. Studies conducted outside the United States follow a different regime. Under 21 CFR 312.120, foreign studies not conducted under an IND can be used to support an application if they meet ethical and quality standards, and financial disclosure obligations attach differently. Investigators in these studies often have no direct FDA-facing duty; the sponsor carries the certification burden if the study is used in an application.
Investigator-initiated INDs. When an investigator holds the IND and is also the sponsor, the roles merge. That investigator-sponsor files the 3454 or 3455 as part of the application. Here the investigator does report to the FDA, but only because the investigator is also the sponsor. The underlying rule is unchanged: the sponsor files.
Transfer of sponsorship. If sponsorship transfers mid-study, the incoming sponsor inherits the certification obligation. The outgoing sponsor's prior disclosures remain relevant, and the new sponsor must reconcile the investigator's financial history.
Certification versus disclosure form. Form 3454 is the certification that no disclosable interests exist or that interests were disclosed and managed. Form 3455 is the disclosure statement listing the actual interests. Sponsors file one or the other, not both, for a given investigator. Choosing 3454 when a 3455 is required is a sponsor error, and investigators should flag it when they see their disclosures summarized incorrectly.
Red flags that should prompt a site to escalate:
A sponsor asks the investigator to sign a blank or pre-completed financial disclosure form. The sponsor's payment ledger shows amounts above USD 25,000 that the disclosure form omits. A study coordinator with equity in the sponsor is not asked to disclose. The site receives a request to send a 3454 or 3455 to an FDA address directly. Disclosures are collected only at study start and never updated despite changes. Payment timing is restructured to keep individual payments below USD 25,000 while aggregate payments exceed it.
Comparing the roles and the forms
The table below maps who does what across the disclosure chain, so sites can see where their obligation ends and the sponsor's begins.
| Role | Document or action | Reported to | Governing reference |
|---|---|---|---|
| Investigator | Financial interest disclosure | Sponsor | 21 CFR 54.4 |
| Sub-investigator | Disclosure through site lead | Sponsor | 21 CFR 54.2, 54.4 |
| Sponsor | Form 3454 certification | FDA | 21 CFR 54.4, 54.6 |
| Sponsor | Form 3455 disclosure statement | FDA | 21 CFR 54.4, 54.6 |
| Investigator-sponsor (IIT) | 3454 or 3455 in application | FDA | 21 CFR 54.6 |
| FDA reviewer | Evaluate disclosed interest | Internal review | 21 CFR 54.6 |
| Site coordinator | Collect and track updates | Investigator | Contract and 21 CFR 54.4 |
The row that causes the most confusion is the investigator-sponsor row. Only IIT holders who also hold the IND file with the FDA, and they file in their sponsor capacity. A site investigator employed by a sponsor but not holding the IND still reports to that sponsor.
Timeline: from study start to application
Disclosure obligations follow a defined arc, and sites that treat the form as a one-time signature miss the update requirements.
| Stage | Timing | Responsible party | Action |
|---|---|---|---|
| Study start | Before first subject enrolled | Investigator | Initial disclosure to sponsor |
| Enrollment | On study start | Sponsor | Collect and verify disclosures |
| Change in interest | Within days of change | Investigator | Updated disclosure to sponsor |
| Study completion | At last visit | Investigator | Final disclosure to sponsor |
| One year post-study | 12 months after completion | Investigator | Confirm no new interests |
| Application submission | With marketing application | Sponsor | File 3454 or 3455 |
| FDA review | During application review | FDA | Evaluate disclosed interests |
| Inspection | Post-approval or for-cause | FDA | Verify disclosure records |
The one-year tail is often neglected. Payments that arrive after the study closes, including milestone or consulting fees, can push an investigator over the USD 25,000 threshold and trigger a late disclosure. Sites should build a calendar reminder for the 12-month mark.
Practical actions for sites and sponsors
For sites, the first step is a written disclosure procedure that names the responsible party and the update cadence. The procedure should define what counts as a reportable interest, including family holdings and equity, and should require re-signature at study close and at the one-year mark.
For investigators, the practical test is simple. If aggregate payments from the sponsor will exceed USD 25,000, or if the investigator holds equity or a proprietary interest, disclose it. Disclose early. Disclose updates. Keep a copy of every submitted form.
For sponsors, the certification decision requires a reconciliation between payment records and investigator disclosures. A sponsor that files 3454 while its own ledger shows reportable payments has created a submission integrity risk that FDA inspection can surface.
Concrete thresholds and steps:
USD 25,000 aggregate payment threshold, measured across the study plus one year. Any equity interest in the sponsor, at any value, is disclosable. Any proprietary interest in the product under study is disclosable. Reconcile payment ledgers against disclosures before filing the application. Retain disclosure records for at least the period the application remains active, and longer if litigation is foreseeable. Train coordinators on the difference between 3454 and 3455 so misfiling is caught before submission.
The reconciliation point deserves emphasis. Multiple thresholds coexist in practice: the USD 25,000 payment trigger, the any-value equity trigger, and the any-value proprietary interest trigger. Sites sometimes apply the USD 25,000 figure to equity and conclude no disclosure is needed. That is wrong. The money threshold governs payments only. Equity and proprietary interests have no dollar floor.
Limitations and what this explainer cannot settle
This article describes the federal disclosure framework and the division of reporting responsibility. It does not interpret a specific site's contract, state law, or institutional policy, each of which can impose stricter requirements than Part 54. Some institutions require disclosure of any payment regardless of amount, and some sponsors add contractual reporting duties that exceed the regulation. The federal rule is a floor, not a ceiling.
The article also cannot predict how the FDA will weigh a particular disclosed interest, because that judgment is case-specific and rests with reviewers. Nor can it resolve whether a given individual meets the regulatory definition of clinical investigator; that determination depends on the person's actual role in subject treatment and evaluation. Sites with borderline cases should consult their institutional counsel or regulatory affairs office.
This article is general educational information about regulatory reporting responsibilities, not a legal opinion or a compliance determination for any specific study. It does not promise any inspection outcome or approval result. Readers should consult qualified regulatory counsel or their institutional review office for advice about a particular study or disclosure.